/CRDL.TO

CRDL.TO Stock - Cardiol Therapeutics Inc.

Q: What is the analyst price target for CRDL.TO?

Analyst price target information is not currently available for CRDL.TO.

Q: What is CRDL.TO's market cap?

Market capitalization information is not currently available for CRDL.TO.

Healthcare|Drug Manufacturers - Specialty & Generic|TSX

$1.40-1.41%

$0.02 (-1.41%) • Dec 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.54

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CRDL.TO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.82

52W High$2.17

52W Low$1.09

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	$78,760	N/A
Gross Profit	$-373,114	$-248,355	$-219,908	$78,760	$-229,539
Gross Margin	N/A	N/A	N/A	100.0%	N/A
Operating Income	$-40,276,651	$-29,785,504	$-50,339,034	$-45,473,128	$-20,606,480
Net Income	$-36,677,299	$-28,128,291	$-11,522,260	$-24,723,916	$-20,648,333
Net Margin	N/A	N/A	N/A	-31391.5%	N/A
EPS	$-0.51	$-0.44	$-0.18	$-0.57	$-0.69

Company Overview

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Visit Website

Earnings History & Surprises

CRDL.TO

Beat Rate

56%

Last 18 quarters

Avg Surprise

+2.5%

EPS vs Estimate

Beats / Misses

10/5

3 met exactly

Latest EPS

$-0.12

Q4 2025

EPS Surprise History

Q4 23

+25.0%

$-0.09vs$-0.12

Q1 24

0.0%

$-0.12vs$-0.12

Q2 24

0.0%

$-0.12vs$-0.12

Q3 24

+23.1%

$-0.10vs$-0.13

Q4 24

-50.0%

$-0.18vs$-0.12

Q4 24

+21.1%

$-0.10vs$-0.13

Q2 25

+30.8%

$-0.09vs$-0.13

Q4 25

-6.9%

$-0.12vs$-0.11

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 12, 2026	—	—	—	—
Q4 2025	Nov 18, 2025	$-0.11	$-0.12	-6.9%	✗ MISS
Q2 2025	May 12, 2025	$-0.13	$-0.09	+30.8%	✓ BEAT
Q4 2024	Dec 31, 2024	$-0.13	$-0.10	+21.1%	✓ BEAT
Q4 2024	Nov 14, 2024	$-0.12	$-0.18	-50.0%	✗ MISS
Q3 2024	Aug 12, 2024	$-0.13	$-0.10	+23.1%	✓ BEAT
Q2 2024	Apr 1, 2024	$-0.12	$-0.12	0.0%	= MET
Q1 2024	Mar 26, 2024	$-0.12	$-0.12	0.0%	= MET
Q4 2023	Nov 14, 2023	$-0.12	$-0.09	+25.0%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.12	$-0.12	0.0%	= MET
Q2 2023	May 15, 2023	$-0.15	$-0.11	+26.7%	✓ BEAT
Q1 2023	Mar 29, 2023	$-0.15	$-0.12	+20.0%	✓ BEAT
Q4 2022	Nov 10, 2022	$-0.14	$-0.13	+7.1%	✓ BEAT
Q3 2022	Aug 10, 2022	$-0.14	$-0.10	+28.6%	✓ BEAT
Q2 2022	May 16, 2022	$-0.17	$-0.14	+17.6%	✓ BEAT
Q1 2022	Mar 23, 2022	$-0.15	$-0.11	+26.7%	✓ BEAT
Q4 2021	Nov 15, 2021	—	$-0.23	—	—
Q3 2021	Aug 16, 2021	$-0.14	$-0.16	-14.3%	✗ MISS
Q2 2021	May 18, 2021	$-0.14	$-0.26	-85.7%	✗ MISS
Q1 2021	Mar 31, 2021	$-0.12	$-0.15	-25.0%	✗ MISS

Frequently Asked Questions about CRDL.TO

What is CRDL.TO's current stock price?

Cardiol Therapeutics Inc. (CRDL.TO) is currently trading at $1.40 per share. The stock has moved -1.41% today.

What is the analyst price target for CRDL.TO?

No analyst price targets are currently available for this stock.

What sector is Cardiol Therapeutics Inc. in?

Cardiol Therapeutics Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the TSX exchange.

What is CRDL.TO's market cap?

Cardiol Therapeutics Inc. has a market capitalization of $0.12 billion, making it a small-cap company.

Does CRDL.TO pay dividends?

No, Cardiol Therapeutics Inc. does not currently pay a dividend to shareholders.